

Patient Name	: Mr Dummy	Bill Date	: Feb 04, 2024, 09:15 PM
DOB/Age/Gender	: 67 Y/Male	Sample Collected	: Feb 05, 2024, 08:48 AM
Patient ID / UHID	: XXX	Sample Received	: Feb 05, 2024, 12:37 PM
Referred By	: Dr.	Report Date	: Feb 05, 2024, 04:50 PM
Sample Type	: Serum	Report Status	: Final Report
Barcode No	: XXX		

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**BIOCHEMISTRY REPORT**  
**N-Terminal Pro B Type Natriuretic Peptide (NT-Pro BNP)**

NT-Pro-BNP	61.1	pg/mL
Method : CMIA		

**Interpretation:**  
In patients presenting with signs and symptoms of cardiac disease:

**Acute setting (in emergency department)**

Patients' Age	NT-proBNP (pg/mL)	Interpretation and Further Suggestions
Age-stratified Rule-in		
< 50 years	> 450	Acute heart failure is likely. Other confounding factors are to be considered as it may indicate cardiac dysfunction and are associated with an increased risk of other cardiac complications.
50-75 years	> 900	
>75 years	> 1800	
Age-independent Rule-out		
All ages	< 300	Acute heart failure is unlikely. Looking for other symptoms is suggested.

**Non-acute setting (outpatient setting with GP/specialists)**

Non-acute setting (outpatient setting with GP/specialists) 4-8 Patients' Age	NT-proBNP (pg/mL)	Interpretation and Further Suggestions
All ages	≥ 125	Indicative of cardiac dysfunction and are associated with an increased risk of cardiac complications like myocardial infarction, heart failure, death.
All ages	< 125	Cardiac dysfunction can be excluded with a high level of certainty in patients with symptoms suggestive of heart failure e.g. dyspnea

**In patients of type 2 diabetes mellitus without signs and symptoms of cardiac disease**

Patients' Age	NT-proBNP (pg/mL)	Interpretation and Further Suggestions
All ages	≥ 125	Predictive of the occurrence of subsequent cardiovascular events e.g. increased risk of heart failure. Advanced cardiovascular risk assessment and therapy optimization to prevent the development of left ventricular dysfunction or new-onset heart failure are suggested.
All ages	< 125	Suggestive of low risk of subsequent cardiovascular events e.g. low risk of heart failure. Repeating test in 12 months is suggested.

**Use of NTproBNP in clinical settings:**

1. It can aid in the diagnosis of individuals suspected of having congestive heart failure and detection of mild forms of cardiac dysfunction.

*Sohini Sengupta*

Dr. Sohini Sengupta  
MD (Cl Biochemistry), DNB,  
FNB (Lab Medicine)  
Medical Laboratory Director  
HOD (Biochemistry & Special Assays)



Booking Centre :- HOME COLLECTION - NOIDA - F10166  
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

☎ 898-898-0606

✉ care@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr Dummy

DOB/Age/Gender : 67 Y/Male

Patient ID / UHID : XXX

Referred By : Dr.

Sample Type : Serum

Barcode No : XXX

Bill Date : Feb 04, 2024, 09:15 PM

Sample Collected : Feb 05, 2024, 08:48 AM

Sample Received : Feb 05, 2024, 12:37 PM

Report Date : Feb 05, 2024, 04:50 PM

Report Status : Final Report

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

2. It aids in the assessment of heart failure severity in patients diagnosed with congestive heart failure., and risk stratification of patients with acute coronary syndrome & congestive heart failure.
3. It can help in the cardiovascular risk assessment of patients with type 2 diabetes mellitus.
4. It aids in the identification of patients at risk with type 2 diabetes mellitus without known history of cardiovascular disease, to optimize cardio-protective treatment.
5. It can also be used to identify elderly individuals at high-risk for atrial fibrillation.

Dummy Report

Disclaimer: This is a sample report. The method and reference range in the actual report might vary as per lab accreditation or certification and equipments where sample is processed.

*Sohini Sengupta*

Dr. Sohini Sengupta  
MD (Cl Biochemistry), DNB,  
FNB (Lab Medicine)  
Medical Laboratory Director  
HOD (Biochemistry & Special Assays)



Booking Centre :- HOME COLLECTION - NOIDA - F10166

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

☎ 898-898-0606

✉ [care@redcliffelabs.com](mailto:care@redcliffelabs.com)🌐 [www.redcliffelabs.com](http://www.redcliffelabs.com)

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.